Jamshedpur, Aug 16: The number of COVID-19 positive cases crossed 3600 as over 100 fresh cases were again reported in the city on Sunday. The city also witnessed four more deaths taking the final toll figures at Tata Main Hospital ( TMH) to around 134 till afternoon. Out of four deaths two were men and other two were women. ��
During a telephonic media interaction, Dr Rajan Choudhry, general manager, medical services, Tata Steel said that Remdesivir and Favipiravir is already being used in indicated cases, Tocilizumab is expected to be available soon. TMH is also adding Ivermectin and Doxycycline to its COVID-19 treatment protocol.
The first death was reported on July 4 when two elderly persons, including an 88-year-old woman died in the Tata Main Hospital.
The prime health hub of Jamshedpur city is managing 1087 beds for COVID-19 management which includes 661 beds for COVID positive patients, 112 numbers of routine isolation beds, 18 ICU isolation beds and 36 ICU COVID beds. TMH is equipped with 83 ventilators for the critical patients. This includes managing 100 beds at hotel Sonnet and 160 beds at hotel Ginger for COVID positive patients with continuous onsite monitoring by TMH doctors and nurses. TMH has a team of over 350 doctors and over 2000 paramedical staff.
TMH has set up 2 COVID screening centres in Jamshedpur. The hospital since April 24 has conducted 20000 COVID-19 RT-PCR test (as on August 14)
TMH so far has managed a total 1686 (as on August 14) COVID positive cases. Out of which, 1133 have recovered and discharged. Number of active cases is 460. The recovery rate for COVID at TMH is about 67%.
It is continuing with its emergency services besides catering to COVID patients. TMH has set up a special COVID-19 Maternity and Labour Room Complex for suspect/confirmed pregnant women.
After due approvals, the Jamshedpur Blood Bank harvested convalescent plasma from the 1st two such donors on 31st July 2020. TMH has already received confirmation from the ICMR stating that �convalescent plasma can be used for COVID-19 on a case to case basis as an off label, experimental therapy after proper evaluation of the patient and taking consent from the patient. The first two indicated patients have received convalescent therapy on August 1. Convalescent plasma has been used in four indicated patients till date (as on Aug. 14). One of the patients has recovered from COVID and has been discharged.
